Welcome to our dedicated page for NEPHROS SEC filings (Ticker: NEPH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Nephros Inc. filings document formal disclosures for a water technology company selling filtration solutions to medical and commercial markets. Recent 8-K reports furnish operating results and financial condition updates, Regulation FD presentations, and material event disclosures tied to the company's product, service, and education strategy.
The filing record also includes a material definitive agreement with Medica S.p.A. covering license and supply arrangements for filtration products based on Medisulfone ultrafiltration technology. These disclosures describe contractual rights, supply obligations, product commercialization arrangements, and related public-company reporting matters.
Nephros Inc. President and CEO Robert R. Banks Jr. exercised stock options to acquire 120,000 shares of common stock at $1.44 per share on March 23, 2026. Following the transaction, he directly holds 190,000 common shares and retains a remaining option position tied to 10,406 underlying shares expiring in 2034.
Nephros Inc. Chief Financial Officer Judy Krandel exercised stock options to acquire 68,861 shares of common stock at an exercise price of $1.71 per share. The options were previously granted compensation awards. Following the transaction, she directly holds 68,861 common shares.
She also continues to hold stock options over 54,359 shares at an exercise price of $1.68 per share, expiring on March 27, 2035, and options over 4,000 shares at an exercise price of $2.92 per share, expiring on March 16, 2036. Footnotes describe future vesting schedules for these remaining option grants. No open-market purchases or sales were reported in this filing.
Nephros director Arthur H. Amron received a grant of 3,610 shares of Nephros common stock on March 16, 2026, issued in lieu of cash fees for board service. The grant was recorded at a price of $0.00 per share and brings his directly held common stock to 134,882 shares.
He also holds stock options to purchase 7,323 shares at an exercise price of $2.14 per share expiring on May 14, 2034, and options for 7,050 shares at $1.47 per share expiring on January 1, 2035. These options vest in equal annual installments over three years, as described in the filing footnotes.
Nephros Inc.’s Chief Financial Officer Judy Krandel received a stock option grant as part of her compensation. On March 16, 2026, she was granted options to buy 4,000 shares of common stock at an exercise price of $2.92 per share, expiring on March 16, 2036. According to the vesting terms, 1,000 of these options vest on March 16, 2027, and the remaining 3,000 vest in 12 quarterly installments starting on June 16, 2027.
In addition to this new grant, she holds previously awarded options with exercise prices of $1.71 and $1.68 per share that expire in 2033 and 2035, respectively, covering 122,524 and 54,359 underlying shares of common stock. The filing shows only acquisitions and holdings, with no reported sales or dispositions in this report.
Nephros, Inc. files its annual report describing a profitable water-filtration business focused on medical-grade and commercial point-of-use solutions. The company highlights FDA 510(k)-cleared Class II filters for infection control and dialysis, as well as commercial products that now reduce Total PFAS.
Management reports profitability in 2024 and 2025 but an accumulated deficit of $143.1 million and dependence on a few large customers and suppliers. A renewed Medica supply agreement runs through 2030 with rising euro-denominated minimum purchase commitments. Nephros also discloses a material weakness in revenue recognition controls, tariff and cybersecurity risks, and significant ownership concentration by Wexford Capital.
Nephros, Inc. entered a new long-term license and supply agreement with Medica S.p.A. for ultrafiltration products. The deal gives Nephros an exclusive license, with rights to sublicense, to market, promote, distribute, offer for sale and sell certain Medisulfone-based filtration products in a defined territory, while Nephros grants Medica an exclusive license under its intellectual property to make these products during the term.
In return, Nephros committed to minimum annual aggregate purchases from Medica of €4,976,000, €5,349,000, €5,750,000, €6,000,000 and €6,300,000 for the years 2026, 2027, 2028, 2029 and 2030, respectively. The agreement runs through December 31, 2030, and replaces a prior 2023 license and supply agreement that was terminated when this new contract was signed.
Nephros may terminate the agreement for convenience with 90 days’ written notice, while Medica can terminate for uncured monetary defaults, and either party can terminate for material breaches or specified insolvency events. The contract also includes customary representations, warranties and indemnification obligations.
Nephros (NEPH) Form 4: A director reported acquiring 1,622 shares of common stock on 11/10/2025 at $0, held directly following the transaction.
The reporting person also holds a stock option to buy 13,229 shares at $4.49, expiring 08/11/2035. The option vests as to 4,410 shares on 6/16/25, 4,410 shares on 6/16/26, and 4,409 shares on 6/16/27.
Nephros, Inc. (NEPH) filed a Form 4 showing insider activity. A director reported acquiring 8,036 shares of common stock on 11/10/2025 at $0, bringing direct beneficial ownership to 122,881 shares following the transaction. The filing also lists multiple outstanding stock options with various exercise prices and expirations, with examples including options exercisable at $5.5755 expiring 08/10/2028 and at $2.14 expiring 05/14/2034.
Nephros (NEPH) Form 4: A director reported acquiring 5,391 shares of common stock on 11/10/2025 at a price of $0. Following this transaction, the director beneficially owned 131,272 shares directly.
The filing also lists outstanding stock options: 7,323 options with a $2.14 exercise price expiring 05/14/2034 and 7,050 options with a $1.47 exercise price expiring 01/01/2035. The vesting schedules include 2,441 shares on each of 5/14/24, 5/14/25, and 5/14/26 for the first grant, and 2,350 shares on each of 1/1/25, 1/1/26, and 1/1/27 for the second.
Nephros (NEPH) reported strong Q3 2025 results, driven by higher programmatic activity and service growth. Net revenue rose to $4.764M (up 35% year over year), with gross margin steady at 61%. Operating income improved to $0.314M, and net income reached $0.337M (basic and diluted EPS $0.03).
For the nine months, revenue increased to $14.060M (up 37%), gross margin expanded to 63%, and the company swung to $1.132M in net income from a prior loss. Operating cash flow was $1.415M, lifting cash to $5.171M and working capital to $8.239M. SG&A and R&D rose with higher commissions, bonus accruals, and salaries, while interest income increased.
The company notes customer concentration (top accounts comprised 46% of Q3 revenue) and continues to remediate a previously identified revenue recognition control weakness under ASC 606. As of November 3, 2025, 10,626,683 common shares were outstanding.